XNAS
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
Satellos’ quarter was clinically focused rather than financially meaningful, with no revenue and a modest EPS miss of **$0.03** to **($0.56)**. In this biotech setup, the key issue is execution on the pipeline, and this print offers little evidence of a near-term catalyst.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.53 | -0.56 | -5.66% | $0 | ❌ Miss | +0.61% | +3.72% | — |
| 2026-05-15 | Q1 2026 | — | -0.53 | — | $0 | — | +0.00% | -3.71% | -17.97% |
Showing last 2 quarters.